Abera Bioscience seeks Dutch regulatory clearance to start Phase I trial for Ab-01.12 vaccine

• Abera Bioscience filed an application with Dutch regulators to start a Phase 1 trial of pneumococcal nasal vaccine candidate Ab-01.12.
• Radboud University Medical Center is the clinical partner on the proposed study.
• Trial start is targeted for autumn 2026, subject to regulatory review and approvals.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abera Bioscience AB published the original content used to generate this news brief via Cision (Ref. ID: 202607220242BITN____UKPR__SV_20260722-BIT-0929-0) on July 22, 2026, and is solely responsible for the information contained therein.